{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pembrolizumab&page=36", "query": { "intervention": "pembrolizumab", "page": 36 }, "page_size": 10 }, "pagination": { "page": 36, "page_size": 10, "total_count": 837, "total_pages": 84, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pembrolizumab&page=37&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pembrolizumab&page=35&page_size=10" }, "source": "local", "last_synced_at": "2026-10-30T19:38:20.481Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05701527", "title": "A Study of EBC-129 in Advanced Solid Tumours", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumours" ], "interventions": [ { "name": "EBC-129", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EDDC (Experimental Drug Development Centre), A*STAR Research Entities", "sponsor_class": "OTHER_GOV", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2023-04-28", "completion_date": "2026-12-24", "has_results": false, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-10-16T17:58:13.448Z", "location_count": 2, "location_summary": "Aurora, Colorado • Houston, Texas", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05701527" }, { "nct_id": "NCT07183319", "title": "Circulating Tumor DNA Response In Urothelial Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Carcinoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Pembrolizumab & Enfortumab Vedotin (PEV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Oklahoma", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2026-01-19", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-02-02", "last_synced_at": "2026-10-14T06:06:20.497Z", "location_count": 1, "location_summary": "Oklahoma City, Oklahoma", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT07183319" }, { "nct_id": "NCT03804944", "title": "Converting HR+ Breast Cancer Into an Individualized Vaccine", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "CDX-301", "type": "BIOLOGICAL" }, { "name": "Focal Radiation therapy", "type": "RADIATION" }, { "name": "Pembrolizumab (200mg IV for 30 minutes", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION", "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "FEMALE", "summary": "18 Years to 90 Years · Female only" }, "enrollment_count": 100, "start_date": "2020-03-17", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-01-28", "last_synced_at": "2026-10-02T18:45:48.493Z", "location_count": 8, "location_summary": "Los Angeles, California • New York, New York • Pittsburgh, Pennsylvania + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03804944" }, { "nct_id": "NCT06324240", "title": "Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage IA Breast Cancer AJCC v8", "Anatomic Stage IB Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage IIA Breast Cancer AJCC v8", "Anatomic Stage IIB Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Early Stage Triple-Negative Breast Carcinoma", "Locally Advanced Triple-Negative Breast Carcinoma", "Metastatic Triple-Negative Breast Carcinoma", "Prognostic Stage I Breast Cancer AJCC v8", "Prognostic Stage IA Breast Cancer AJCC v8", "Prognostic Stage IB Breast Cancer AJCC v8", "Prognostic Stage II Breast Cancer AJCC v8", "Prognostic Stage IIA Breast Cancer AJCC v8", "Prognostic Stage IIB Breast Cancer AJCC v8", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Prognostic Stage IV Breast Cancer AJCC v8", "Recurrent Breast Carcinoma", "Unresectable Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Vaccine Therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2025-12-02", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-01-26", "last_synced_at": "2026-09-15T14:35:45.763Z", "location_count": 4, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06324240" }, { "nct_id": "NCT05084430", "title": "Study of Pembrolizumab and M032 (NSC 733972)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Anaplastic Astrocytoma", "Glioblastoma Multiforme", "Gliosarcoma" ], "interventions": [ { "name": "M032", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2022-02-25", "completion_date": "2028-03-01", "has_results": false, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-10-03T00:08:49.430Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT05084430" }, { "nct_id": "NCT04995003", "title": "HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ewing Sarcoma", "HER-2 Protein Overexpression", "Osteosarcoma", "Rhabdomyosarcoma", "Sarcoma", "Soft Tissue Sarcoma", "Synovial Sarcoma", "Undifferentiated Sarcoma" ], "interventions": [ { "name": "Nivolumab Injectable Product", "type": "DRUG" }, { "name": "Pembrolizumab Injectable Product", "type": "DRUG" }, { "name": "T cells or CAR T cells", "type": "GENETIC" } ], "intervention_types": [ "DRUG", "GENETIC" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "25 Years", "sex": "ALL", "summary": "1 Year to 25 Years" }, "enrollment_count": 25, "start_date": "2021-12-07", "completion_date": "2043-06-30", "has_results": false, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-10-14T00:50:05.179Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04995003" }, { "nct_id": "NCT05656235", "title": "Renal Retention in High Grade Upper Tract Urothelial Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer", "High Grade Urothelial Carcinoma", "Urothelial Carcinoma Bladder" ], "interventions": [ { "name": "Enfortumab vedotin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2024-11-25", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-01-08", "last_synced_at": "2026-10-14T14:39:12.037Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Baltimore, Maryland", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05656235" }, { "nct_id": "NCT05613413", "title": "A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Squamous Non-Small Cell Lung Carcinoma" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Carboplatin or Cisplatin", "type": "DRUG" }, { "name": "Pacliltaxel or Nab-paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Illinois Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2022-12-28", "completion_date": "2028-09", "has_results": false, "last_update_posted_date": "2026-01-08", "last_synced_at": "2026-10-30T19:38:20.481Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05613413" }, { "nct_id": "NCT05405595", "title": "ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced/Metastatic Solid Tumors" ], "interventions": [ { "name": "ADG126", "type": "DRUG" }, { "name": "Pembrolizumab (KEYTRUDA®)", "type": "DRUG" }, { "name": "Standard of Care (Trifluridine/Tipiracil-Bevacizumab)", "type": "DRUG" }, { "name": "Standard of care (Fruquintinib)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Adagene Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 186, "start_date": "2022-06-15", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-01-07", "last_synced_at": "2026-10-27T17:28:20.969Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • Duarte, California • Irvine, California + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05405595" }, { "nct_id": "NCT07197827", "title": "A Study of YL242 in Subjects With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "YL242", "type": "DRUG" }, { "name": "YL242; 5-FU; LV", "type": "DRUG" }, { "name": "YL242; Pembrolizumab", "type": "DRUG" }, { "name": "YL242; Pembrolizumab; 5-FU", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MediLink Therapeutics (Suzhou) Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 424, "start_date": "2025-09-22", "completion_date": "2028-11", "has_results": false, "last_update_posted_date": "2025-12-24", "last_synced_at": "2026-10-22T18:08:07.059Z", "location_count": 7, "location_summary": "New Haven, Connecticut • Sarasota, Florida • Boston, Massachusetts + 4 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07197827" } ] }